医学
大流行
2型糖尿病
疾病
全球卫生
疾病负担
环境卫生
中低收入国家
糖尿病
经济增长
发展中国家
发展经济学
业务
公共卫生
2019年冠状病毒病(COVID-19)
传染病(医学专业)
经济
护理部
内分泌学
病理
作者
Zulfiqar A Bhutta,Rehana A Salam,Apoorva Gomber,Laura Lewis-Watts,Tanya Narang,Jean Claude Mbanya,George A.O. Alleyne
出处
期刊:The Lancet
[Elsevier BV]
日期:2021-11-01
卷期号:398 (10313): 1837-1850
被引量:28
标识
DOI:10.1016/s0140-6736(21)02247-9
摘要
Type 1 diabetes is on the rise globally; however, the burden of mortality remains disproportionate in low-income and middle-income countries (LMICs). As 2021 marks 100 years since the discovery of insulin, we revisit progress, global burden of type 1 diabetes trends, and understanding of the pathogenesis and management practices related to the disease. Despite much progress, inequities in access and availability of insulin formulations persist and are reflected in differences in survival and morbidity patterns related to the disease. Some of these inequities have also been exacerbated by health-system challenges during the COVID-19 pandemic. There is a clear opportunity to improve access to insulin and related essential technologies for improved management of type 1 diabetes in LMICs, especially as a part of universal health coverage. These improvements will require concerted action and investments in human resources, community engagement, and education for the timely diagnosis and management of type 1 diabetes, as well as adequate health-care financing. Further research in LMICs, especially those in Africa, is needed to improve our understanding of the burden, risk factors, and implementation strategies for managing type 1 diabetes.
科研通智能强力驱动
Strongly Powered by AbleSci AI